Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Pfizer paid $60M upfront with up to $55M in regulatory milestones for global ex-Israel rights to taliglucerase alfa, with revenue/expense shared…
Protalix Form 8-K discloses the exclusive license and supply agreement with Pfizer for taliglucerase alfa, including a $60 million upfront payment and a…
Six years on, Protalix sold its 40% ELELYSO stake to Pfizer for $36M cash plus $10M equity, reflecting modest commercial traction against entrenched Cerezyme.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
$60M upfront + ~$115M milestones for taliglucerase alfa (ELELYSO) for Gaucher disease ex-Israel. Source: Protalix IR, Pfizer press.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Protalix BioTherapeutics, Inc. (this deal) | 2009 | $175M | — |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2009 deals · Pfizer Inc. deals